Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
1994
Strolin Benedetti M.; Marrari P.; Colombo M.; Castelli M.G.; Arand M.; Oesch F and Dostert P.
The Anticonvulsant FCE 26743 Is a Selective and Short-Acting MAO-B Inhibitor Devoid of Inducing Properties Towards Cytochrome P450-Dependent Testosterone Hydroxylation in Mice and Rats
J. Pharm. Pharmacol.; 46: 814-819, 1994